Bionano Transforms in 2025, Optimizes Financial Profile
"2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of OGM both in the U.S. and internationally," commented Erik Holmlin, PhD, president and chief executive officer of Bionano. "We saw important reimbursement progress with the establishment of a second category I CPT code for OGM, this time in constitutional genetic disorders and a 47% increase in payment determination for the category I CPT code for OGM use in hematologic malignancies. We also saw significant expansion in the body of published clinical research evidence in support of using OGM as an alternative to traditional cytogenetic methods, with continued growth both in peer-reviewed publications and reported clinical research genomes. Our teams launched a major upgrade to our software and compute platforms, among other product improvements. As a result, we are entering 2026 with a strong foundation and pipeline of demand."
Trade with 70% Backtested Accuracy
Analyst Views on BNGO
About BNGO
About the author
Bionano Genomics Showcases OGM Technology Enhancing Detection Capabilities
- Technology Showcase: Bionano Genomics presented its Optical Genome Mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional methods, which may drive broader clinical adoption.
- Research Findings: A total of thirteen studies were presented, indicating the increasing application of OGM in areas such as inherited diseases and tumors, showcasing its potential as a high-resolution genomic technique that could transform the study of complex diseases.
- Workflow Optimization: Researchers demonstrated the successful integration of OGM into existing cytogenetics and next-generation sequencing (NGS) pipelines, streamlining laboratory workflows and enhancing efficiency in both clinical and translational research settings.
- Future Outlook: Bionano CEO Erik Holmlin stated that the advancement of OGM will enable comprehensive structural variant analysis to become routine, efficient, and accessible in laboratories, signaling a strategic shift for the company in the genomics field.
Bionano Genomics Showcases OGM Technology for Enhanced Structural Variant Detection
- Technology Application Showcase: Bionano Genomics presented its optical genome mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional techniques, which is expected to drive broader applications in clinical and translational research.
- Research Findings Summary: A total of thirteen studies presented at the conference demonstrated OGM's potential in areas such as inherited diseases and tumors, indicating its capability as a high-resolution genomic technique that could transform the understanding of genetic mechanisms driving complex diseases.
- Laboratory Workflow Optimization: Researchers showcased how OGM can be successfully integrated into existing cytogenetics and next-generation sequencing workflows, streamlining laboratory processes and enhancing detection efficiency, which may improve operational effectiveness in labs.
- Future Development Commitment: Bionano CEO Erik Holmlin stated the company's commitment to innovating and expanding OGM technology, aiming to make comprehensive structural variant analysis routine, efficient, and accessible in laboratories, signaling a promising future market outlook.
Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
- Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
- Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
- Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
- Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
Baidu Expected to Surge Over 69%: 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Price Target Increases: JP Morgan upgraded Cipher Mining Inc and Baidu Inc, raising their price targets significantly, while B of A Securities upgraded Barrick Mining Corp's rating and price target as well.
Analyst Downgrades and Price Target Reductions: HC Wainwright & Co. downgraded BioNano Genomics Inc, and Jefferies downgraded Exact Sciences Corp despite increasing their price targets.
Mixed Analyst Ratings: Various analysts maintained or adjusted ratings for companies like Mp Materials Corp and Flutter Entertainment PLC, with some upgrades and downgrades occurring simultaneously.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
Bionano Genomics Initiates $10 Million Public Offering
Public Offering Announcement: Bionano Genomics, Inc. has launched a public offering of 5 million shares at $2.00 each, aiming to raise $10 million, with potential additional funds of $20 million if warrants are fully exercised.
Strategic Focus and Growth Plans: The company is enhancing utilization of its optical genome mapping and VIA software, aiming to expand into clinical and anatomic pathology while developing reimbursement support to increase profits and reduce costs.
Bionano Genomics, Inc. Completes $10 Million Public Offering
Public Offering Announcement: Bionano Genomics closed a public offering of 5 million shares and associated Series E and F warrants, raising approximately $10 million, with potential additional proceeds of $20 million if the warrants are fully exercised.
Use of Proceeds: The company plans to use the net proceeds from the offering for working capital and general corporate purposes, as outlined in their registration statement with the SEC.
Bionano Genomics Showcases OGM Technology Enhancing Detection Capabilities
- Technology Showcase: Bionano Genomics presented its Optical Genome Mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional methods, which may drive broader clinical adoption.
- Research Findings: A total of thirteen studies were presented, indicating the increasing application of OGM in areas such as inherited diseases and tumors, showcasing its potential as a high-resolution genomic technique that could transform the study of complex diseases.
- Workflow Optimization: Researchers demonstrated the successful integration of OGM into existing cytogenetics and next-generation sequencing (NGS) pipelines, streamlining laboratory workflows and enhancing efficiency in both clinical and translational research settings.
- Future Outlook: Bionano CEO Erik Holmlin stated that the advancement of OGM will enable comprehensive structural variant analysis to become routine, efficient, and accessible in laboratories, signaling a strategic shift for the company in the genomics field.
Bionano Genomics Showcases OGM Technology for Enhanced Structural Variant Detection
- Technology Application Showcase: Bionano Genomics presented its optical genome mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional techniques, which is expected to drive broader applications in clinical and translational research.
- Research Findings Summary: A total of thirteen studies presented at the conference demonstrated OGM's potential in areas such as inherited diseases and tumors, indicating its capability as a high-resolution genomic technique that could transform the understanding of genetic mechanisms driving complex diseases.
- Laboratory Workflow Optimization: Researchers showcased how OGM can be successfully integrated into existing cytogenetics and next-generation sequencing workflows, streamlining laboratory processes and enhancing detection efficiency, which may improve operational effectiveness in labs.
- Future Development Commitment: Bionano CEO Erik Holmlin stated the company's commitment to innovating and expanding OGM technology, aiming to make comprehensive structural variant analysis routine, efficient, and accessible in laboratories, signaling a promising future market outlook.
Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
- Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
- Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
- Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
- Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
Baidu Expected to Surge Over 69%: 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Price Target Increases: JP Morgan upgraded Cipher Mining Inc and Baidu Inc, raising their price targets significantly, while B of A Securities upgraded Barrick Mining Corp's rating and price target as well.
Analyst Downgrades and Price Target Reductions: HC Wainwright & Co. downgraded BioNano Genomics Inc, and Jefferies downgraded Exact Sciences Corp despite increasing their price targets.
Mixed Analyst Ratings: Various analysts maintained or adjusted ratings for companies like Mp Materials Corp and Flutter Entertainment PLC, with some upgrades and downgrades occurring simultaneously.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
Bionano Genomics Initiates $10 Million Public Offering
Public Offering Announcement: Bionano Genomics, Inc. has launched a public offering of 5 million shares at $2.00 each, aiming to raise $10 million, with potential additional funds of $20 million if warrants are fully exercised.
Strategic Focus and Growth Plans: The company is enhancing utilization of its optical genome mapping and VIA software, aiming to expand into clinical and anatomic pathology while developing reimbursement support to increase profits and reduce costs.
Bionano Genomics, Inc. Completes $10 Million Public Offering
Public Offering Announcement: Bionano Genomics closed a public offering of 5 million shares and associated Series E and F warrants, raising approximately $10 million, with potential additional proceeds of $20 million if the warrants are fully exercised.
Use of Proceeds: The company plans to use the net proceeds from the offering for working capital and general corporate purposes, as outlined in their registration statement with the SEC.
